Literature DB >> 20079391

RNA interference in vitro and in vivo using an arginine peptide/siRNA complex system.

Sung Wook Kim1, Na Young Kim, Yu Bin Choi, Seo Hyun Park, Jai Myung Yang, Sungho Shin.   

Abstract

Efficient delivery systems are required to exploit the enormous potential of RNA interference. We introduced an arginine peptide-based small-interference RNA (siRNA) delivery system for in vitro and in vivo RNA interference. Arginine peptides formed stable complexes with siRNA and transduced siRNA into COS-7 cells in vitro, resulting in efficient gene silencing. The intracellular path of the peptide/siRNA complex was investigated in live cells using fluorescent labeling and confocal microscopy. At 24h after transfection, most of the siRNA signals were observed in the perinuclear region, indicating that siRNA was targeted to the perinuclear region for interactions with RNA-induced silencing complex (RISC). Effective in vivo RNA interference was achieved in a mouse model bearing a subcutaneous tumor. Intratumoral administration of HER-2-specific siRNA/peptide complexes resulted in a marked reduction of tumor growth. Body weight monitoring during treatment showed that our delivery system was nontoxic. Our approach offers the potential for siRNA delivery in various in vitro and in vivo applications. 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20079391     DOI: 10.1016/j.jconrel.2010.01.009

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  30 in total

1.  Poly-L-arginine and dextran sulfate-based nanocomplex for epidermal growth factor receptor (EGFR) siRNA delivery: its application for head and neck cancer treatment.

Authors:  Hyun-Jong Cho; Saeho Chong; Suk-Jae Chung; Chang-Koo Shim; Dae-Duk Kim
Journal:  Pharm Res       Date:  2011-12-15       Impact factor: 4.200

Review 2.  Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides.

Authors:  Johannes Winkler
Journal:  Ther Deliv       Date:  2011-07

3.  Humanized Lewis-Y specific antibody based delivery of STAT3 siRNA.

Authors:  Yuelong Ma; Claudia M Kowolik; Piotr M Swiderski; Marcin Kortylewski; Hua Yu; David A Horne; Richard Jove; Otavia L Caballero; Andrew J G Simpson; Fook-Thean Lee; Vinochani Pillay; Andrew M Scott
Journal:  ACS Chem Biol       Date:  2011-07-26       Impact factor: 5.100

Review 4.  Peptide carriers to the rescue: overcoming the barriers to siRNA delivery for cancer treatment.

Authors:  James C Cummings; Haiwen Zhang; Andrew Jakymiw
Journal:  Transl Res       Date:  2019-07-29       Impact factor: 7.012

5.  Lipidoid-siRNA Nanoparticle-Mediated IL-1β Gene Silencing for Systemic Arthritis Therapy in a Mouse Model.

Authors:  Ping Song; Chuanxu Yang; Jesper Skovhus Thomsen; Frederik Dagnæs-Hansen; Maria Jakobsen; Annemarie Brüel; Bent Deleuran; Jørgen Kjems
Journal:  Mol Ther       Date:  2019-05-15       Impact factor: 11.454

Review 6.  Functional peptides for siRNA delivery.

Authors:  Wanyi Tai; Xiaohu Gao
Journal:  Adv Drug Deliv Rev       Date:  2016-08-13       Impact factor: 15.470

7.  Guanabenz (Wytensin™) selectively enhances uptake and efficacy of hydrophobically modified siRNAs.

Authors:  Maire F Osborn; Julia F Alterman; Mehran Nikan; Hong Cao; Marie C Didiot; Matthew R Hassler; Andrew H Coles; Anastasia Khvorova
Journal:  Nucleic Acids Res       Date:  2015-09-22       Impact factor: 16.971

8.  MITF-siRNA formulation is a safe and effective therapy for human melasma.

Authors:  Xiang Yi; Guang Zhao; Hongjie Zhang; Di Guan; Rusong Meng; Yingyu Zhang; Qingqi Yang; Henming Jia; Kejun Dou; Chui Liu; Fangyuan Que; James Q Yin
Journal:  Mol Ther       Date:  2010-11-30       Impact factor: 11.454

9.  Melittin derived peptides for nanoparticle based siRNA transfection.

Authors:  Kirk K Hou; Hua Pan; Gregory M Lanza; Samuel A Wickline
Journal:  Biomaterials       Date:  2013-02-04       Impact factor: 12.479

10.  Arginine-rich, cell penetrating peptide-anti-microRNA complexes decrease glioblastoma migration potential.

Authors:  Yu Zhang; Melanie Köllmer; Jason S Buhrman; Mary Y Tang; Richard A Gemeinhart
Journal:  Peptides       Date:  2014-06-23       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.